The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis

Jianting Long; Shi Fang; Qiangsheng Dai; Xiaolian Liu; Wanshou Zhu; Shenming Wang

doi:10.18632/oncotarget.8117

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis

Jianting Long, Shi Fang, Qiangsheng Dai, Xiaolian Liu, Wanshou Zhu _ and Shenming Wang

PDF | HTML | How to cite

Oncotarget. 2016; 7:32079-32087. https://doi.org/10.18632/oncotarget.8117

Metrics: PDF 2482 views | HTML 2491 views | ?

Abstract

Jianting Long1,*, Shi Fang2,*, Qiangsheng Dai1, Xiaolian Liu3, Wanshou Zhu3, Shenming Wang4

1Department of Medicinal Oncology, The First Affiliated Hospital, SUN Yat-Sen University, Guangzhou 510080, China

2Department of Clinic Nutrition, The First Affiliated Hospital, SUN Yat-Sen University, Guangzhou 510080, China

3Department of Hematology, Gaozhou People’s Hospital, Gaozhou 525200, China

4Department of Vascular Surgery, The First Affiliated Hospital, SUN Yat-Sen University, Guangzhou 510080, China

*These authors are co-first authors

Correspondence to:

Wanshou Zhu, email: [email protected]

Shenming Wang, email: [email protected]

Keywords: acute myeloid leukemia, Wilms’ tumor gene 1, association, meta-analysis

Received: November 18, 2015 Accepted: February 23, 2016 Published: March 16, 2016

ABSTRACT

Although a number of studies suggested that WT1 rs16754 polymorphism might be related to decreased relapse free survival (RFS) and overall survival (OS). The results remain controversial. Published reports were searched in PubMed, EMBASE, and Google Scholar. Twelve publications with 3903 patients had met the inclusion criteria and were subjected to further examination. We found WT1 rs16754 polymorphism was significantly associated with OS in AML (OR = 0.62; 95% CI 0.52 – 0.75; p < 0.00001; I² = 47%). WT1 rs16754 polymorphism was also significantly associated with RFS in AML (OR = 0.69; 95% CI 0.57 – 0.83; p < 0.001; I² = 46%). In the subgroup analyses of age, race, and subtype of AML, WT1 rs16754 polymorphism was a independent favorable-risk marker. In conclusion, WT1 rs16754 polymorphism is associated with better survival of AML. It could be used as a cost-effective prognostic biomarker for AML.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8117

Publication Alerts

Research Papers:

The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis

Abstract